80O - Determinants of survival in 7.214 patients with stage III NSCLC treated with chemoradiotherapy in the Netherlands

Date 28 March 2014
Event ELCC 2014
Session Proffered papers 4 - SCLC and locally advanced NSCLC
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Locally Advanced
Surgery and/or Radiotherapy of Cancer
Presenter Jose Belderbos
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors J. Belderbos1, J. Widder2, H. Groen3, R.A. Damhuis4
  • 1Radiation Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 2Radiation Oncology, University Medical Center Groningen, Groningen/NL
  • 3Pulmonology, University Medical Center Groningen, Groningen/NL
  • 4None, Comprehensive Cancer Centre, Utrecht/NL


Chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) is a curative treatment that involves sequential or concurrent chemotherapy. The landmark meta-analysis by Auperin (2010) reported a five-year survival of 10.6% in sequential setting, as opposed to 15.1% in concurrent setting. However, that analysis comprised only 1205 patients and most of these had been treated before the year 2000. Since then, modern radiation techniques (IMRT, image guided RT) and staging examinations (FDG-PET and brain CTscan or MRI) were introduced. In the Netherlands, a national guideline was introduced in 2004, advocating concurrent CRT, but chemo- and radiotherapy regimes are known to differ between regions. The aim of our study was to assess time trends and regional differences in overall survival (OS) for patients receiving CRT.